---
title: "Tonghua Dongbao Pharmaceutical Co.,Ltd. (600867.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600867.SH.md"
symbol: "600867.SH"
name: "Tonghua Dongbao Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T16:46:43.061Z"
locales:
  - [en](https://longbridge.com/en/quote/600867.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600867.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600867.SH.md)
---

# Tonghua Dongbao Pharmaceutical Co.,Ltd. (600867.SH)

## Company Overview

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug treatment, blood glucose monitoring, and patient education.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.thdb.com](https://www.thdb.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.25)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 15 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 47.05% |  |
| Net Profit YoY | 934.27% |  |
| P/B Ratio | 2.37 |  |
| Dividend Ratio | 2.83% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17187352139.38 |  |
| Revenue | 3048791295.27 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 18.01% | A |
| Profit Margin | 40.64% | A |
| Gross Margin | 71.62% | A |
| Revenue YoY | 47.05% | A |
| Net Profit YoY | 934.27% | A |
| Total Assets YoY | 9.31% | B |
| Net Assets YoY | 11.16% | B |
| Cash Flow Margin | 68.98% | C |
| OCF YoY | 47.05% | A |
| Turnover | 0.39 | C |
| Gearing Ratio | 12.27% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tonghua Dongbao Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "47.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "934.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.83%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "17187352139.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3048791295.27",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "18.01%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "40.64%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "71.62%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "47.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "934.27%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.31%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.16%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "68.98%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "47.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.39",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "12.27%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 13.59 | 6/215 | 39.94 | 14.41 | 13.85 |
| PB | 2.32 | 108/215 | 2.65 | 2.47 | 2.36 |
| PS (TTM) | 5.52 | 138/215 | 7.42 | 6.38 | 6.14 |
| Dividend Yield | 2.89% | 35/215 | 2.99% | 2.86% | 2.74% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Overweight | 1 | 25% |
| Sell | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.58 |
| Highest Target | 11.26 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600867.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600867.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600867.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600867.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**